Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of IntegraMed America, Inc. (“IntegraMed” or the “Company”) (NASDAQ GM: INMD) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by Sagard Capital Partners, L.P. (“Sagard”) in a transaction valued at approximately $169.5 million.

Click here to learn more: http://www.rigrodskylong.com/investigations/integramed-america-inc-inmd.

Under the terms of the proposal, public shareholders of IntegraMed will receive $14.05 per share in cash for each share of IntegraMed they own.

The investigation concerns whether IntegraMed’s board of directors failed to adequately shop the Company and obtain the best possible price for IntegraMed’s shareholders before entering into an agreement with Sagard. At least one analyst on Yahoo! Finance has issued a $17.00 per share target price for IntegraMed.

If you own the common stock of IntegraMed and purchased your shares before June 11, 2012, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Peter Allocco at Rigrodsky & Long, P.A., 825 East Gate Boulevard, Suite 300, Garden City, New York 11530 toll free at (888) 969-4242, by e-mail to info@rigrodskylong.com, or at: http://www.rigrodskylong.com/investigations/integramed-america-inc-inmd.

Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly prosecutes securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, on behalf of shareholders in states and federal courts throughout the United States.

Attorney advertising. Prior results do not guarantee a similar outcome.